References
- Nguyen, K. V. Problems Associated with Antiviral Drugs and Vaccines Development for COVID-19: approach to Intervention Using Expression Vectors via GPI Anchor. Nucleos. Nucleot. Nucleic Acids 2021, 40, 665–706. DOI: 10.1080/15257770.2021.1914851.
- Nguyen, K. V.; Naviaux, R. K.; Nyhan, W. L. Lesch-Nyhan Disease: I. Construction of Expression Vectors for Hypoxanthine-Guanine Phosphoribosyltransferase (HGprt) Enzyme and Amyloid Precursor Protein (APP). Nucleos. Nucleot. Nucleic Acids 2020, 39, 905–922. DOI: 10.1080/15257770.2020.1714653.
- Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N. G.; Decroly, E. The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furin-like Cleavage Site absent in CoV of the Same Clade. Antiviral. Res. 2020, 176, 104742. DOI: 10.1016/j.antiviral.2020.104742.
- Baer, C. F. Does Mutation Rate Depend on Itself. PLoS Biol. 2008, 6, e52. DOI: 10.1371/journal.pbio.0060052.
- Cuevas, J. M.; Geller, R.; Garijo, R.; Aldeguer, J. L.; Sanjua, R. Extremely High Mutation Rate of HIV-1 in Vivo. PLoS Biol. 2015, 13, e1002251. DOI: 10.1371/journal.pbio.1002251.
- Stem, A.; Andino, R. Viral Evolution. It is All about Mutations. In Viral Pathogenesis, Chapter 17; Elsevier Ltd, Amsterdam, Netherlands, 2016; pp. 233–240. DOI: 10.1371/journal.pbio.3000003.
- Sanjuan, R.; Domingo-Calap, P. Mechanisms of Viral Mutation. Cell Mol. Life Sci. 2016, 73, 4433–4448. DOI: 10.1007/s00018-016-2299-6.
- Duffy, S. Why Are RNA Virus Mutation Rates so Damn High? PLoS Biol. 2018, 16, e3000003. DOI: 10.1371/journal.pbio.3000003.
- Hurst, L. “What we know so far about the B. 1.1.529 Omicron COVID variant causing concern” 26 November, 2021. https://www.euronews.com/next/2021/11/25/what-we-know-so-far-about-the-b-1-1-529-covid-variant-causing-concern-in-south-africa. Euronews. Archived (https://web.archive.org/web/20211126195100/https:/www.euronews.com/next/2021/11/25/what-we-know-so-far-about-the-b-1-1-529-covid-variant-causing-concern-in-south-africa. from the original on 26 November 2021. (accessed 26 November 2021).
- William, A. H. “Omicron Origins”, 2021. (https://www.forbes.com/sites/williamhaseltine/2021/12/02/omicron-origins/?sh=297d8f961bc1). Forbes. Archived (https://web.archive.org/web/2021/12/02/omicron-origins/) from the original on 3 December 2021. (accessed 4 December 2021).
- Cookson, C.; Barnes, O. “What We Know About Omicron Variant that Has Sparked Global Alarm”, 2021. (https://www.ft.com/content/42c5ff3d-e676-4076-9b9f-7243a00cba5e). Financial Times. Archived (https://web.archive.org/web/20211126181037/https://www.ft.com/content/42c5ff3d-e676-4076-9b9f-7243a00cba5e) from the original on 26 November 2021. (accessed 26 November 2021).
- Callaway, E. Heavily Mutated Coronavirus Variant Puts Scientist on Alert. Nature 2021, 600, 21–21. (https://www.nature.com/articles/d41586-021-03552-W). (). PMID 34824381 (https://pubmed.ncbi.nlm.nih.gov/34824381)/S2CID 244660616 (https://api.semanticscholar.org/CorpusID: 244660616). Archived (https://web.archive.org/web/20211126181902/ https://www.nature.com/articles/d41586-021-03552-W) from the original on 26 November 2021. (accessed 26 November 2021). DOI: 10.1038/d41586-021-03552-w.
- Zimmer, C. “New Virus Variant Stokes Concern but Vaccines Still Likely to Work”, 2021. (https://www.nytimes.com/2021/11/26/health/omicron-variant-vaccines.html). New York Times. Archived (https://web.archive.org/web/2021126232026/https://www.nytimes.com/2021/11/26/health/omicron-variant-vaccines.html) from the original on November 2021. (accessed 26 November 2021).
- Zhang, L.; Mann, M.; Syed, Z. A.; Reynolds, H. M.; Tian, E.; Samara, N. L.; Zeldin, D. C.; Tabak, L. A.; Ten Hagen, K. G. “ Furin Cleavage of the SARS-CoV-2 Spike is Modulated by O-Glycosylation. Proc. Natl. Acad. Sci. U.S.A 2021, 118, e2109905118. (23 November (). PMID 34732583 (https://pubmed.ncbi.nlm.nih.gov/34732583). S2CID 242937417 (https://api.semainticscholar.org/CorpusID:242937417). DOI: 10.1073/pnas.2109905118.
- “Implication of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA”, 2021. (https://www.ecdc.europa.eu/sites/default/files/documents/Implications-emergence-spread-SARS-CoV-2%20B.1.1.529-variant-concern-Omicron-for-the-EU-EEA-Nov2021.pdf) (PDF). Ecdc.europa.eu. Archived (https://web.archive.org/web/20211126212442/https://www.ecdc.europa.eu/sites/default/files/documents/Implications-emergence-spread-SARS-CoV-2%20B.1.1.529-variant-concern-Omicron-for-the-EU-EEA-Nov2021.pdf. ) (PDF) from the original on 26 November 2021. (accessed 26 November 2021).
- Sun, W.; Liao, J. P.; Qiu, J. X.; Que, C. L.; Wang, G. F.; Ma, J. A Severe Case of Human Coronavirus 229E Pneumonia in an Elderly Man with Diabetes Mellitus: A Case Report. BMC Infect. Dis. 2021, 21, 524.
- Breslin, J. J.; Mork, I.; Smith, M. K.; Vogel, L. K.; Hemmila, E. M.; Bonavia, A.; Talbot, P. J.; Sjostrom, H.; Noren, O.; Holmes, K. V. Human Coronavirus 229E: Receptor Binding Domain and Neutralization by Soluble Receptor at 37 °C. J. Virol. 2003, 77, 4435–4438.
- World Health Organization. Update on SARS-CoV-2 Variant of Concern Omicron. 2022. https://cdn.who.int/media/docs/default-source/epi-win/webinar-report-epi-win/presentation_sylvie_briand.pdf?sfvrn=f036d40a_5.
- Colson, P.; Delerce, J.; Burel, E.; Dahan, J.; Jouffret, A.; Fenollar, F.; Yahi, N.; Fantini, J.; La Scola, B.; Raoult, D. Emergence in Southern France of a New SARS-CoV-2 Variant of Probably Cameroonian Origin Harbouring Both Substitutions N501Y and E484K in the Spike Protein. medRxiv preprint, 2021 doi: (DOI: 10.1101/2021.12.24.21268174.; this version posted December 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
- Pavan, M.; Bolcato, G.; Bassani, D.; Sturlese, M.; Moro, S. Supervised Molecular Dynamics (SuMD) Insights into the Mechanism of Action of SARS-CoV-2 Main Protease Inhibitor PF-07321332. J. Enzyme Inhib. Med. Chem 2021, 36, 1646–1650. (https://www.ncbi.nlm.gov/pmc/articles/PMC8300928). DOI: 10.1080/14756366.2021.1954919.(). PMC 8300928 (https://www.ncbi.ncbi.nlm.nih.gov/pmc/articles/PMC8300928.). PMID34289752 (https://pubmed.ncbi.nlm.nih.gov/34289752).
- Woodley, M. “What is Australia’s Potential New COVID Treatment?”, 2021. (https://www.1.racgp.org.au/newsgp/clinical/what-is-australia-s-potential-new-covid-treatment). The Royal Australian College of General Practitioners (RACGP). Retrieved 6 November 2021.
- Liu, C.; Ginn, H. M.; Dejnirattisa, W.; Supasa, P.; Wang, B.; Tuekprakhon, A.; Nutalai, R.; Zhou, D.; Mentzer, A. J.; Zhao, Y.; et al. Reduced Neutralization of SARS-CoV-2 B.1.617 by Vaccine and Convalescent Serum. Cell 2021, 184, 4220–4236. DOI: 10.1016/j.cell.2021.06.020.
- Duong, D. Alpha, Beta, Delta, Gamma: What’s Important to Know About SARS-CoV-2 Variants of Concern? CMAJ 2021, 193, E1059–60. DOI: 10.1503/cmaj.1095949.
- Samavati, L.; Uhal, B. D. ACE2, Much More than Just a Receptor for SARS-CoV-2. Front Cell Infect Microbiol 2020, 10, 317. DOI: 10.3389/fcimb.2020.00317.
- Scialo, F.; Daniele, A.; Amato, F.; Pastore, L.; Matera, M. G.; Cazzola, M.; Castaldo, G.; Bianco, A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 2020, 198, 867–877. DOI: 10.1007/s00408-020-00408-4.
- Coates, D. The Angiotensin Converting Enzyme (ACE). Int. J. Biochem. Cell Biol. 2003, 35, 769–773. (https://pubmed.ncbi.nlm.nih.gov/12676162. ). DOI: 10.1016/S1357-2725(02)00309-6.
- Nguyen, G. Renin, (Pro)Renin and Receptor: An Update. Clin. Sci. (Lond) 2011, 120, 169–178. DOI: 10.1042/CS20100432.
- Chung, O.; Csikos, T.; Unger, T. Angiotensin II Receptor Pharmacology and AT1-Receptor Blocker. J. Hum. Hypertens 1999, 13, S11–S20. DOI: 10.1038/sj.jhh.1000744.
- Kaschina, E.; Unger, T. SignalingAngiotensin Receptors: Structure, Function, Signaling and Function. Blood Press 2003, 12, 70–88. DOI: 10.1080/08037050310001057.
- Singh, K. D.; Karnik, S. S. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J. Cell Signal 2016, 1. 1–8. DOI: 10.4172/jcs.1000111.
- Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, L.; Guo, R.; Chen, T.; Hu, J.; et al. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV. Nat. Commun. 2020, 11, 1620. DOI: 10.1038/s41467-020-15562-9.
- Sriram, K.; Insel, P. A. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence. Clin. Pharmacol. Ther. 2020, 108, 236–241. DOI: 10.1002/cpt.1863.
- Lee, S. J.; Kim, T.; Cho, W. H.; Jeon, D.; Lim, S. Possible Benefit of Angiotensin II Receptor Blockers in COVId-19 Patients: A Case Series. J. Renin-Angiotensin-Aldosterone Syst. 2021, 2021, 1–6. DOI: 10.1155/2021/9951540.
- Wang, G.; Yang, M. L.; Duan, Z. L.; Liu, F. L.; Jin, L.; Long, C. B.; Zhang, M.; Tang, X. P.; Xu, L.; Li, Y. C.; et al. Dalbavancin Binds ACE2 to Block Its Interaction with SARS-CoV-2 Spike Protein and is Effective in Inhibiting SARS-CoV-2 Infection in Animal Models. Cell Res. 2021, 31, 17–24. DOI: 10.1038/s41422-020-00450-0.
- Colafella, K. M.; Uijl, E.; Danser, J. Interference with the Renin-Angiotensin System (RAS): Classical Inhibitors and Novel Approaches. Encyclopedia of Endocr. Dis. 2019, 3, 523–530. DOI: 10.1016/b978-0-12-801238-3.65341-2.. ISBN 978-0-12-812200-6. S2CID 86384280. https://api.semanticsholar.org/CorpusID:86384280.
- Monteil, V.; Kwon, H.; Prado, P.; Hagelkruys, A.; Wimmer, R. A.; Stahl, M.; Leopoldi, A.; Garreta, E.; del Pozo, C. H.; Prosper, F.; et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell 2020, 181, 905–913. DOI: 10.1016/j.cell.2020.04.004.
- Fillardi, P. P. ACEi and ARBS in Hypertension and Hearth Failure; Springer International Publishing: Switzerland, 2015; Vol. 5; pp 10–13. ISBN 978-3-319-09787-9.
- Dicpinigaitis, P. V. Angiotensin-Converting Enzyme Inhibitor-Induced Cough: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2006, 129, 169S–173S. DOI: 10.1378/chest.129.1_suppl.169S.
- Hemming, M. L.; Selkoe, D. J. Amyloid Beta-Protein is Degraded by Cellular Angiotensin-Converting Enzyme (ACE) and Elevated by an ACE Inhibitor. J. Biol. Chem 2005, 280, 37644–37650. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409196. (. ). PMC 2409196 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409196. PMID 16154999 https://pubmed.ncbi.nlm.nih.gov/16154999. DOI: 10.1074/jbc.M508460200.
- Kowalczuk, S.; Broer, A.; Tietze, N.; Vanslambrouck, J. M.; Rasko, J. E.; Broer, S. A Protein Complex in the Brush-Border Membrane Explains a Hartnup Disorder Allele. Faseb J. 2008, 22, 2880–2887. PMID 18424768 https://pubmed.ncbi.nlm.nih.gov/18424768. DOI: 10.1096/fj.08-107300.
- Turner, A. J. Chapter 25: ACE2 Cell Biology, Regulation, and Physiological Functions. In The Protective Arm of the Renin-Angiotensin System (RAS): Functional Aspects and Therapeutic Implications; Unger, T.; Ulrike, M.; Steckelings, U. M.; dos Santos, R. A., Eds.; Academic Press, Elsevier Inc. Amsterdam, Netherlands, 2015; pp. 185–189. DOI: 10.1016/B978-0-12-801364-9.00025-0. ISBN 978-0-12-801364-9. S2CID 88645177 https://api.semanticsholar.org/CorpusID:88645177.
- Leung, P. S. The Peptide Hormone Angiotensin II: its New Functions in Tissues and Organs. Curr. Protein Pept. Sci. 2004, 5, 267–273. DOI: 10.2174/1389203043379693.
- Sward, P.; Edsfeldt, A.; Reepalu, A.; Jehpsson, L.; Rosengren, B. E.; Karlsson, M. K. Age and Sex Differences in Soluble ACE2 May Give Insights for COVID-19. Crit. Care 2020, 24, 221.
- “Climate Change and Infectious Diseases” https://www.who.int/globalchange/climate/en/chapter6.pdf. (PDF). Climate Change and Human Health-Risk and Responses. World Health Organization. Archived https://web.archive.org/web/20160304063626/http://www.who.int/globalchange/climate/en/chapter6.pdf. (PDF) from the original on 2016. 2016.
- “Climate Change and Human Health-Risks and Responses. Summary” 2018. https://www.who.int/globalchange/climate/summay/en/index5.html. www.who.int. (accessed 29 October 2018).
- Frutos, R.; Gavotte, L.; Devaux, C. A. Understanding the Origin of COVID-19 Requires to Change the Paradigm on Zoonotic Emergence from the Spillover to the Circulation Model. Infect. Genet. Evol. 2021, 95, 104812. DOI: 10.1016/j.meegid.2021.104812.
- Guarner, F.; Malagelada, J. Gut Flora in Health and Disease. The Lancet 2003, 361, 512–519. DOI: 10.1016/S0140-6736(03)12489-0.
- Sears, C. L. A Dynamic Partnership: celebrating Our Gut Flora. Anaerobe 2005, 11, 247–251. DOI: 10.1016/j.anaerobe.2005.05.001.
- Robertson, D. L.; Hahn, B. H.; Sharp, P. M. Recombination in AIDS Viruses. J. Mol. Evol. 1995, 40, 249–259. DOI: 10.1007/BF00163230.
- Rambaut, A.; Posada, D.; Crandall, K. A.; Holmes, E. C. The Causes and Consequences of HIV Evolution. Nat. Rev. Genet. 2004, 5, 52–61. DOI: 10.1038/nrg1246.
- Perelson, A. S.; Ribeiro, R. M. Estimating Drug Efficacy and Viral Dynamic Parameters: HIV and HCV. Stat. Med. 2008, 27, 4647–4657. DOI: 10.1002/sim.3116.
- Kim, J.; Vasan, S.; Kim, J. H.; Ake, J. A. Current Approaches to HIV Vaccine Development: A Narrative Review. JIAS 2021, 24, e25793.
- Hargrave, A.; Mustafa, A. S.; Hanif, A.; Tunio, J. H.; Hanif, S. N. M. Current Status of HIV-1 Vaccines. Vaccines 2021, 9, 1026. DOI: 10.3390/vaccines9091026.
- Stein, S. R.; Ramelli, S. C.; Grazioli, A.; Chung, J. J.; Singh, M.; Yinda, C. K.; Winkler, C. W.; Dickey, J. M.; Ylaya, K.; Ko, S. H.; et al. SARS-CoV-2 Infection and Persistence throughout the Human Body and Brain. Research Square 2021, (Posted date: December 20th (Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information). DOI: 10.21203/rs.3.rs-/v1.